Australia's most trusted
source of pharma news
Sunday, 02 November 2025
Posted 30 October 2025 AM
The global atrial fibrillation (AF) market is about to take a big hit, thanks largely to generic sales of novel oral anticoagulants (NOACs), according to analytics company GlobalData.
AF sales in the eight major markets (8MM): the US, France, Germany, Italy, Spain, the UK, Canada and Japan will fall from US$14.5 billion in 2022 to US$10.5 billion in 2032, according to a GlobalData forecast, equating to a negative compound annual growth rate (CAGR) of 3.2 per cent.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.